These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32865564)

  • 21. Generic substitution does not seem to affect adherence negatively in elderly polypharmacy patients.
    Olesen C; Harbig P; Barat I; Damsgaard EM
    Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1093-8. PubMed ID: 24038668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors influencing the use of the "not for generic substitution" mention for prescriptions in primary care: a survey with general practitioners.
    Beauvais V; Marque A; Ferté G; Chrusciel J; Souille J; Nazeyrollas P; Sanchez S
    BMC Health Serv Res; 2018 Nov; 18(1):850. PubMed ID: 30419890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors Associated With Generic Drug Uptake in the United States, 2012 to 2017.
    Rome BN; Lee CC; Gagne JJ; Kesselheim AS
    Value Health; 2021 Jun; 24(6):804-811. PubMed ID: 34119078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trends of generic substitution in community pharmacies.
    Suh DC
    Pharm World Sci; 1999 Dec; 21(6):260-5. PubMed ID: 10658234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential savings associated with drug substitution in Medicare Part D: the Translating Research into Action for Diabetes (TRIAD) study.
    Duru OK; Ettner SL; Turk N; Mangione CM; Brown AF; Fu J; Simien L; Tseng CW
    J Gen Intern Med; 2014 Jan; 29(1):230-6. PubMed ID: 23975059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
    Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
    Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens.
    Contin M; Alberghini L; Candela C; Benini G; Riva R
    Epilepsy Res; 2016 May; 122():79-83. PubMed ID: 26987080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determinants of Generic Drug Substitution in the United States.
    Segal JB; Onasanya O; Daubresse M; Lee CY; Moechtar M; Pu X; Dutcher SK; Romanelli RJ
    Ther Innov Regul Sci; 2020 Jan; 54(1):151-157. PubMed ID: 32008244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generic Substitution and Advice to Patients -Potential Legal Medicine Consequences - From A (Australia) to U (United Kingdom or United States of America).
    Beran RG
    Seizure; 2021 Oct; 91():515-519. PubMed ID: 33840583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.
    Haas JS; Phillips KA; Gerstenberger EP; Seger AC
    Ann Intern Med; 2005 Jun; 142(11):891-7. PubMed ID: 15941695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Norwegian patients on generic antihypertensive drugs: a qualitative study of their own experiences.
    Toverud EL; Røise AK; Hogstad G; Wabø I
    Eur J Clin Pharmacol; 2011 Jan; 67(1):33-8. PubMed ID: 21104408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The content of patient counseling about interchangeable medicines and generic substitution in Finnish community pharmacies - a survey of dispensers.
    Rainio R; Ahonen R; Timonen J
    BMC Health Serv Res; 2019 Dec; 19(1):956. PubMed ID: 31829174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential savings from generic prescribing and generic substitution in South Africa.
    Karim SS; Pillai G; Ziqubu-Page TT; Cassimjee MH; Morar MS
    Health Policy Plan; 1996 Jun; 11(2):198-205. PubMed ID: 10158460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug product selection: legal issues.
    Christensen TP; Kirking DM; Ascione FJ; Welage LS; Gaither CA
    J Am Pharm Assoc (Wash); 2001; 41(6):868-74. PubMed ID: 11765112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statistical and regulatory considerations in assessments of interchangeability of biological drug products.
    Tóthfalusi L; Endrényi L; Chow SC
    Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S5-11. PubMed ID: 24832831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacists' experiences and attitudes regarding generic drugs and generic substitution: two sides of the coin.
    Olsson E; Kälvemark Sporrong S
    Int J Pharm Pract; 2012 Dec; 20(6):377-83. PubMed ID: 23134096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding State Regulation of Biosimilars and Effect on Prescribers.
    Yale K; Awosika O; Rengifo-Pardo M; Ehrlich A
    J Drugs Dermatol; 2017 Oct; 16(10):995-1000. PubMed ID: 29036253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reconsidering the scope of US state laws allowing pharmacist substitution of generic drugs.
    Darrow JJ; Chong JE; Kesselheim AS
    BMJ; 2020 Jun; 369():m2236. PubMed ID: 32576554
    [No Abstract]   [Full Text] [Related]  

  • 40. A GUIDE TO FOLLOW-ON BIOLOGICS AND BIOSIMILARS WITH A FOCUS ON INSULIN.
    Dolinar R; Lavernia F; Edelman S
    Endocr Pract; 2018 Feb; 24(2):195-204. PubMed ID: 29466056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.